Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 144 participants.

Also called NCT01117987

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 144 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01117987
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Austria, Belgium, Canada, France, Germany, Italy, Japan, Netherlands, South Korea, Spain, Switzerland, United Kingdom (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01117987. Non-randomized; no masking; primary purpose treatment. Start 2010-04 (registry gives no type); primary completion 2014-04 (actual). Results posted on 2015-05-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)
Acronym
IMPRES Extn
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Imatinib
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01117987
Content hash
8e260a7dc22e53b21308130c125fd645bf6cffa27d86524d96b24d5aca1fc19d